EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
Thursday, Virax Biolabs Group Limited (NASDAQ: VRAX) announced it is launching 'ImmuneSelect' within the ViraxImmune T-Cell diagnostic platform for research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress.
週四，Virax Biolabs集團有限公司（納斯達克股票代碼：VRAX）宣佈，將在2024年歐洲臨床微生物學和傳染病學會全球大會上，在Virax免疫T細胞診斷平台（RUO）內推出 “ImmuneSelect”，僅供研究使用。
"We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
Virax Biolabs首席執行官詹姆斯·福斯特先生評論說：“我們很高興推出ImmuneSelect，這是我們ViraxImmune T細胞診斷平台中重要的免疫分析解決方案組合。”
"The launch marks a significant milestone for Virax, as it brings us a step closer to commercializing ViraxImmune as a full in-Vitro Diagnostic product."
“此次發佈標誌着Virax的一個重要里程碑，因爲它使我們離將ViraxImmune作爲一款完整的體外診斷產品的商業化又近了一步。”
ImmuneSelect is the company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.
ImmuneSelect是該公司新的免疫分析解決方案組合，專門用於研究適應性免疫。
ImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID.
ImmuneSelect旨在評估T細胞驅動的免疫力，並幫助理解和及早描述與病毒後綜合徵（包括長期COVID）相關的症狀。
Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool.
ImmuneSelect 品牌的產品僅用於研究和研究，不打算用作診斷工具。
The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens linked to post-viral syndromes.
ImmuneSelect產品組合包括肽庫，涵蓋與病毒後綜合徵相關的病原體的表位。
These include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (CD8), Lyme Disease, Cytomegalovirus, Respiratory Syncytial Virus, and Epstein-Barr Virus.
其中包括SARS-CoV-2、SARS-CoV-2 MHC-1（CD8）、萊姆病、鉅細胞病毒、呼吸道合胞病毒和愛潑斯坦-巴爾病毒庫。
ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications, including Flow Cytometry, ELISA, and ELISpot/Fluorospot.
ImmuneSelect的重組抗體靶向細胞因子和生物標誌物，它們有不同版本可供選擇，未經偶聯，可在包括流式細胞術、ELISA和elispot/FluoroSpot在內的一系列應用中進行測試。
Dr. Nigel McCracken, the Chief Operations Officer of Virax Biolabs, said, "We believe there is great potential to utilize T-Cell diagnostics to help detect underlying post-viral infections by initially measuring the body's adaptive immune resistance to infections and then monitoring the potential progression of an individual's T-Cell functions following chronic antigen stimulation."
Virax Biolabs首席運營官奈傑爾·麥克克拉肯博士說：“我們認爲，通過首先測量人體對感染的適應性免疫抵抗力，然後監測個人T細胞功能在慢性抗原刺激後的潛在進展，利用T細胞診斷來幫助檢測潛在的病毒後感染，潛力巨大。”
Price Action: VRAX shares closed at $0.66 on Wednesday.
價格走勢：VRAX股價週三收於0.66美元。
譯文內容由第三人軟體翻譯。